Carrick Therapeutics
An oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies.
The Irish company is building a portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.
In December 2022, Carrick announced it had raised $25 million in a Series C financing that will fund ongoing and planned samuraciclib clinical trials, ongoing development of its CDK12/13 inhibitor/Cyclin-K glue-degrader, and for working capital and general corporate purposes.
Latest Carrick Therapeutics News & Features
20 December 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze